Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (38)
  • Open Access

    ARTICLE

    Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy

    Yue-shen Wang*1, Jing Tian†1, Yong Han, Shu-mei Han, Sheng-bin Shi

    Oncology Research, Vol.24, No.2, pp. 129-135, 2016, DOI:10.3727/096504016X14618564639213

    Abstract We evaluated the efficacy and feasibility of the combination of gemcitabine plus vinorelbine in patients with platinum-based chemotherapy-refractory esophageal cancer. We enrolled 35 patients who received gemcitabine plus vinorelbine as second-line treatment after platinum-based chemotherapy failure between May 2009 and April 2012. Dosage: gemcitabine 1,000 mg/m2 plus vinorelbine 25 mg/m2 ; all drugs were administered on days 1 and 8 of a 21-day cycle, and this was continued until failure or unacceptable toxicity. A total of 125 cycles of treatment were administered, and all patients received at least two cycles of treatment (two to five cycles;… More >

  • Open Access

    ARTICLE

    Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

    Guanling Chen1, Zhaoze Guo1, Minfeng Liu, Guangyu Yao, Jianyu Dong, Jingyun Guo, Changsheng Ye

    Oncology Research, Vol.25, No.9, pp. 1567-1578, 2017, DOI:10.3727/096504017X14897173032733

    Abstract Capecitabine has consistently demonstrated high efficacy and acceptable tolerability in salvage chemotherapy for advanced breast cancer. However, there remains no consensus on its role in adjuvant chemotherapy for early breast cancer (EBC). To estimate the value of capecitabine-based combination adjuvant treatment in EBC, eight randomized controlled trials with 14,072 participants were analyzed. The efficacy and safety outcomes included disease-free survival (DFS), overall survival (OS), relapse, breast cancer-specific survival (BCSS), and grades 3–5 adverse events. Capecitabine-based combination adjuvant chemotherapy demonstrated a 16% increase in BCSS (HR = 0.84, 95% CI = 0.71–0.98, p = 0.03) in the… More >

  • Open Access

    ARTICLE

    Phase II Trial of Intensity-Modulated Radiotherapy Concurrent With Chemotherapy for Postoperative Node-Positive Esophageal Squamous Cell Carcinoma

    Hua Tao, Yiqin Zhou, Chengyun Yao, Dayong Gu, Wei Chen, Jincheng Lu

    Oncology Research, Vol.25, No.8, pp. 1357-1362, 2017, DOI:10.3727/096504017X14889842609577

    Abstract The aim of this study was to evaluate the efficacy and toxicity of intensity-modulated radiotherapy concurrent with weekly docetaxel in patients with node-positive esophageal squamous cell carcinoma after radical surgery. Between January 2011 and December 2013, a total of 46 eligible patients were enrolled. All patients received intensity-modulated radiotherapy concurrent with weekly docetaxel (20 mg/m2 ). Patients were treated 5 days per week at 2.0 Gy/day. The total dose of external radiotherapy given was 50 Gy in 25 fractions. The primary endpoints included treatment completion and safety. The secondary endpoint was to assess whether the approach… More >

  • Open Access

    ARTICLE

    Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction

    Shoumiao Li*†, Baozhong Li, Jiaxiang Wang*, Da Zhang*, Zhiqiang Liu, Zhizhong Zhang, Wei Zhang, Yunjie Wang, Dongxiao Bai, Jianyun Guan, Yong Zhang

    Oncology Research, Vol.25, No.1, pp. 93-97, 2017, DOI:10.3727/096504016X14719078133564

    Abstract The identification of reliable predictors of chemotherapy sensitivity and early screening of adenocarcinoma of gastroesophageal junction (AGEJ) patients who are resistant to chemotherapy has become an important area of clinical and translational research. We aimed to investigate the predictive value of seven cancerassociated cellular proteins for neoadjuvant chemotherapy in AGEJ patients. Clinical data of 93 patients who received neoadjuvant chemotherapy for locally advanced AGEJ between June 2010 and December 2014 were reviewed. All patients were administered the combination regimen of S-1 and oxaliplatin (SOX). Expression of P-glycoprotein (P-gp), glutathione S-transferase-p (GST-π), topoisomerase II (topo II),… More >

  • Open Access

    ARTICLE

    Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution

    Wang Fangzheng*†1, Jiang Chuner‡1, Ye Zhiming*†, Liu Tongxin*†, Yan Fengqin*†, Wang Lei*†, Li Bin*†, Hu Fujun*†, Chen Ming*†, Qin Weifeng*†, Fu Zhenfu*†

    Oncology Research, Vol.26, No.2, pp. 277-287, 2018, DOI:10.3727/096504017X15079846743590

    Abstract In this retrospective review of a single institution’s experience, the efficacy and safety of the long-term use of nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC) were studied. Between August 2008 and March 2014, 39 newly diagnosed patients with stages III–IV NPC were treated with IMRT, chemotherapy, and nimotuzumab. Twenty patients were diagnosed with stage III (51.3%), 14 with stage IVA (35.9%), and 5 with stage IVB (12.8%) disease. All patients received at least one cycle of cisplatin-based induction chemotherapy followed by IMRT and more… More >

  • Open Access

    ARTICLE

    Efficacy and Safety of Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemotherapy Infusion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

    Xinyang Liu*1, Zhichao Wang*1, Zongwei Chen†1, Longzi Liu*, Lijie Ma*, Liangqing Dong*, Zhao Zhang*, Shu Zhang*, Liuxiao Yang*, Jieyi Shi*, Jia Fan*‡, Xiaoying Wang*, Qiang Gao*‡

    Oncology Research, Vol.26, No.2, pp. 231-239, 2018, DOI:10.3727/096504017X15051752095738

    Abstract Hepatocellular carcinoma (HCC) is a worldwide health threat with increasing incidence and a high mortality rate. Most HCC patients are diagnosed at an advanced stage and are unable to undergo potential curative surgery. Transcatheter arterial chemoembolization (TACE) and transcatheter arterial chemotherapy infusion (TACI) are two of the main palliative treatments for advanced HCC patients. The clinical efficacy and safety of TACE and TACI are controversial. For this reason, we conducted a systematic review and meta-analysis to summarize the current evidence. We searched for randomized controlled trials (RCTs) and cohort studies that compared the clinical outcomes… More >

  • Open Access

    ARTICLE

    Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of GNAL in glioma

    ZHEN LIU1,#, LIANGWANG YANG2,#, ZHENGXING XIE1, HUI YU3, TIANYI GU3, DAOMING SHI4, NING CAI1,*, SHENGHUA ZHUO2,*

    Oncology Research, Vol.32, No.5, pp. 965-981, 2024, DOI:10.32604/or.2024.045769

    Abstract Clinical data indicates that glioma patients have poor treatment outcomes and clinical prognosis. The role of olfactory signaling pathway-related genes (OSPRGs) in glioma has not been fully elucidated. In this study, we aimed to investigate the role and relationship between OSPRGs and glioma. Univariate and multivariate Cox regression analyses were performed to assess the relationship between OSPRGs and the overall survival of glioma based on public cohorts, and the target gene (G Protein Subunit Alpha L, GNAL) was screened. The association of GNAL expression with clinicopathological characteristics, gene mutation landscape, tumor immune microenvironment (TIME), deoxyribonucleic acid… More >

  • Open Access

    REVIEW

    Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review

    EFFAT ALEMZADEH1, LEILA ALLAHQOLI2, AFROOZ MAZIDIMORADI3, ESMAT ALEMZADEH1,4, FAHIMEH GHASEMI4,5, HAMID SALEHINIYA6, IBRAHIM ALKATOUT7,*

    Oncology Research, Vol.32, No.5, pp. 831-847, 2024, DOI:10.32604/or.2024.031006

    Abstract Ovarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for maintenance therapy. However, resistance to these new drugs has emerged. Therefore, understanding the mechanisms of DR and exploring new approaches to overcome More >

  • Open Access

    ARTICLE

    Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects

    QIAN HU, MENGYAO WANG, JINJIN WANG, YALI TAO, TING NIU*

    Oncology Research, Vol.32, No.4, pp. 753-768, 2024, DOI:10.32604/or.2023.043647

    Abstract Multiple myeloma (MM) is a hematologic malignancy notorious for its high relapse rate and development of drug resistance, in which cell adhesion-mediated drug resistance plays a critical role. This study integrated four RNA sequencing datasets (CoMMpass, GSE136337, GSE9782, and GSE2658) and focused on analyzing 1706 adhesion-related genes. Rigorous univariate Cox regression analysis identified 18 key prognosis-related genes, including KIF14, TROAP, FLNA, MSN, LGALS1, PECAM1, and ALCAM, which demonstrated the strongest associations with poor overall survival (OS) in MM patients. To comprehensively evaluate the impact of cell adhesion on MM prognosis, an adhesion-related risk score (ARRS)… More >

  • Open Access

    ARTICLE

    Identifying and validating MMP family members (MMP2, MMP9, MMP12, and MMP16) as therapeutic targets and biomarkers in kidney renal clear cell carcinoma (KIRC)

    KUNLUN LI1, DANDAN LI2, BARBOD HAFEZ3,*, MOUNIR M. SALEM BEKHIT4, YOUSEF A. BIN JARDAN4, FARS KAED ALANAZI4, EHAB I. TAHA4, SAYED H. AUDA4, FAIQAH RAMZAN5,*, MUHAMMAD JAMIL6

    Oncology Research, Vol.32, No.4, pp. 737-752, 2024, DOI:10.32604/or.2023.042925

    Abstract Kidney Renal Clear Cell Carcinoma (KIRC) is a malignant tumor that carries a substantial risk of morbidity and mortality. The MMP family assumes a crucial role in tumor invasion and metastasis. This study aimed to uncover the mechanistic relevance of the MMP gene family as a therapeutic target and diagnostic biomarker in Kidney Renal Clear Cell Carcinoma (KIRC) through a comprehensive approach encompassing both computational and molecular analyses. STRING, Cytoscape, UALCAN, GEPIA, OncoDB, HPA, cBioPortal, GSEA, TIMER, ENCORI, DrugBank, targeted bisulfite sequencing (bisulfite-seq), conventional PCR, Sanger sequencing, and RT-qPCR based analyses were used in the… More >

Displaying 1-10 on page 1 of 38. Per Page